6. Glycemic Targets: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
Diabetes care, 2025 - diabetesjournals.org
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
Type 2 diabetes
Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …
worldwide. The number affected is increasing rapidly with alarming trends in children and …
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
[HTML][HTML] Long-term complications in youth-onset type 2 diabetes
TODAY Study Group - New England Journal of Medicine, 2021 - Mass Medical Soc
Background The prevalence of type 2 diabetes in youth is increasing, but little is known
regarding the occurrence of related complications as these youths transition to adulthood …
regarding the occurrence of related complications as these youths transition to adulthood …
Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized …
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
Trajectories of kidney function in diabetes: a clinicopathological update
M Oshima, M Shimizu, M Yamanouchi… - Nature Reviews …, 2021 - nature.com
Diabetic nephropathy has been traditionally diagnosed based on persistently high
albuminuria and a subsequent decline in glomerular filtration rate (GFR), which is widely …
albuminuria and a subsequent decline in glomerular filtration rate (GFR), which is widely …
Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update
SD Navaneethan, S Zoungas, ML Caramori… - Annals of internal …, 2023 - acpjournals.org
Description: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in
Chronic Kidney Disease is an update of the 2020 guideline from Kidney Disease: Improving …
Chronic Kidney Disease is an update of the 2020 guideline from Kidney Disease: Improving …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …